Welcome to UroSens

UroSens develops and commercialises point-of-care tests for cancers of the urinogenitary tract for use in the urology clinic or doctor's surgery. The initial target is bladder cancer, the fifth most common cancer in the UK with the highest recurrence rate of any malignancy.

The company's key technology provides a highly sensitive and specific test, based on intellectual property exclusively licensed from Cancer Research Technology Ltd, the technology transfer arm of Cancer Research UK.

The current gold standard test for bladder cancer is cystoscopy, an invasive and expensive endoscopic procedure. UroSens' test, under development, requires only a sample of urine which is analysed for the presence of a specific protein using a highly sensitive potentiometric detection system.

The test matches closely the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes.

To contact UroSens please email: info@urosens.com or see our contact page.

csl 2511